Hyperhidrosis

Brickell Biotech Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors Targeting Autoimmune and Inflammatory Diseases from Carna Biosciences

Retrieved on: 
Wednesday, February 2, 2022
Private Securities Litigation Reform Act, Leadership, DNA, Inflammation, Patient, Intellectual property, Insurance, Policy, Trial of the century, Rheumatoid arthritis, SEC, JASDAQ, Cytokine, DYRK1A, Autoimmunity, COVID-19, Collection, Program, Drug discovery, Hyperhidrosis, BBI, Precision medicine, Stimulator of interferon genes, Carna, NCE, Carna, County Galway, GLOBE, Acquisition, Degenerative disease, Humanitarian use licenses, Time, Therapy, Extracellular space, Interferon, U.S. Securities and Exchange Commission, Nasdaq, Pharmaceutical industry, Brickell, Research

BOULDER, Colo. and KOBE, Japan, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory and other debilitating diseases, and Carna Biosciences, Inc. (“Carna") (JASDAQ: 4572), a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative therapies to treat serious unmet medical needs, today announced that they have entered into a licensing agreement, whereby Brickell will have the exclusive, worldwide rights to develop and commercialize Carna’s portfolio of novel, potent, and orally available Stimulator of Interferon Genes (STING) antagonists. STING is a well-known mediator of innate immune responses. Excessive signaling through STING is linked to a number of high unmet need diseases, ranging from autoimmune disorders, such as systemic lupus erythematosus and rheumatoid arthritis, to interferonopathies, which are a set of rare genetic conditions characterized by interferon overproduction.

Key Points: 
  • In many chronic inflammatory conditions, persistent inflammation results in substantial tissue damage and release of DNA fragments into the extracellular space.
  • These assets position us with two promising and novel immunology targets and we look forward to advancing them further throughout this year.
  • Under the terms of the license agreement, Brickell will make a one-time cash payment to Carna of $2.0 million.
  • Brickell Biotech, Inc. is a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases.

Dermatologist Dr. Cybele Fishman of Advanced Dermatology Provides Tips on Alternative Uses for Botox®

Retrieved on: 
Thursday, January 20, 2022
Muscle, Patient, Allergan, Inc., Migraine, Eye, Mouth, Injection, Exercise, Scalp, Hyperhidrosis, Suite, AbbVie, Neurotoxin, Death, American Academy, Physician, Continuum, BOTOX, Center, Neck pain, Skin, Eyebrow, Paralysis, Goal, Smart contract, Plastic surgery, Perspiration, Head, Forehead, Genetics, Spasms, Neck, MD, Muscular system, Botulism, Torticollis, Headache, Exocrine gland, American Academy of Dermatology, Cosmetics, Pharmaceutical industry, Dermatology

Botox acts on muscle cells and, as we've learned over time, there are almost endless applications for its beneficial effects."

Key Points: 
  • Botox acts on muscle cells and, as we've learned over time, there are almost endless applications for its beneficial effects."
  • "There are many more proven uses for Botox," says Dr. Fishman.
  • Dr. Fishman also advises to be careful of Med Spas where Botox is offered very inexpensively.
  • Cybele Fishman, MD , is a board-certified dermatologist, a fellow of the American Academy of Dermatology.

Turn Back the Clock with Cutting-Edge Beauty Treatments from Skinsation LA

Retrieved on: 
Wednesday, January 5, 2022
American Board of Commissioners for Foreign Missions, Huntington Hospital, Radio, Radio-frequency skin tightening, Lip, Hyperhidrosis, Skin, Blemish, Skin cancer, American Board of Internal Medicine, Hair removal, Internal medicine, GLOBE, Skin discoloration, Perspiration, Cosmetics

Its time to turn to Skin Tightening, Botox, and Lip Fillers by Skinsation LA , West Hollywoods premier medical spa.

Key Points: 
  • Its time to turn to Skin Tightening, Botox, and Lip Fillers by Skinsation LA , West Hollywoods premier medical spa.
  • From rejuvenating anti-aging and age reversal treatments to embarrassing conditions, including hyperhidrosis, or excessive sweating, Skin Tightening, Botox, and Lip Fillers by Skinsation LA has the solution for any client.
  • Skin Tightening, Botox, and Lip Fillers by Skinsation LA offers a full array of the most effective treatments availableleaving clients walking away feeling rejuvenated, confident, and beautiful.
  • Skinsation LA is a medical spa offering clients the very latest beauty treatments as well as the most cutting-edge technology to address all skin concerns.

Turn Back the Clock with Curated Medical Botox Treatments at Scottsdale’s Number One Medical Spa

Retrieved on: 
Wednesday, January 5, 2022
Online, Face, Filler (animal food), Forehead, Hyperhidrosis, Neck, Goal, Migraine, Life, Trust, DNP, Mouth, Toxin (comics), Katie, Woman, PDO, GLOBE, Cherry, Man, Perspiration, Risk management, Deoxycholic acid, Botulinum toxin

Look no further than Botox and Fillers By Curated Medical Scottsdale, Arizonas number one medical spa, offering a luxury aesthetic and anti-aging experience.

Key Points: 
  • Look no further than Botox and Fillers By Curated Medical Scottsdale, Arizonas number one medical spa, offering a luxury aesthetic and anti-aging experience.
  • Created by Katie Mann, DNP, FNP-C, Curated Medical is proud to offer the highest quality aesthetic treatments, including Botox and Fillers , in Scottsdale and surrounding areas.
  • Botox and Fillers By Curated Medical is proud to offer Botox (onabotulinumtoxinA), one of the worlds most popular injectable anti-aging treatments.
  • Located in a state-of-the-art facility, Curated Medical is the number one medical spa in Scottsdale, Arizonaoffering modern technologies in a luxurious spa environmentwith top-of-the-line amenities.

Global Axillary Hyperhidrosis Market Opportunity Assessment and Forecast Report 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 15, 2021
Health, Other Health, Epidemiology, Insurance, Education, Hyperhidrosis, Perspiration, Life, Awareness, Diagnosis, Contact dermatitis, Growth, AH, Industry, D, Genetics, Exocrine gland, Review, Skin, Disease, Therapy, Deodorant, Attention deficit hyperactivity disorder predominantly inattentive, Disorder, Axilla, Wool, Medical device, Pharmaceutical industry

The "Axillary Hyperhidrosis - Opportunity Assessment and Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Axillary Hyperhidrosis - Opportunity Assessment and Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The main driver to growth in the AH market is the sales of high-priced neuromuscular blockades represents the most impactful driver of growth for the AH market.
  • What are the main R&D trends in the axillary hyperhidrosis market and which companies are leading the way?
  • Topline AH market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.

RedHill Biopharma's Movantik® Added as Preferred and Unrestricted Brand To Major National Medicare Formulary Serving Millions of Americans

Retrieved on: 
Wednesday, December 1, 2021
Patient, Clarithromycin, Ketoconazole, Anxiety, Diverticulitis, Brain, OIC, Nausea, Chills, Medicare, Multiple sclerosis, Cancer, Traffic barrier, PAMORA, Headache, GI, Flatulence, Alzheimer's disease, Abdominal pain, Chronic pain, Obstruction, Ischemic colitis, Nasdaq, Risk, Hyperhidrosis, Diarrhea, Adult, Irritability, Yawn, Methadone, Medicare Part D, Formulary, CYP3A4, Vomiting, TEL, Redhill, Opioid, Excipient, Diverticular disease, Bevacizumab, Analgesic, Epilepsy, Pharmaceutical industry

"This important new listing for Movantik, the market-leading PAMORA for opioid-induced constipation, as a preferred and unrestricted brand on a major National Medicare Part D formulary provides that access to more than 10 million more Americans covered by this formulary.

Key Points: 
  • "This important new listing for Movantik, the market-leading PAMORA for opioid-induced constipation, as a preferred and unrestricted brand on a major National Medicare Part D formulary provides that access to more than 10 million more Americans covered by this formulary.
  • Patients with known or suspected gastrointestinal (GI) obstruction and patients at risk of recurrent obstruction, due to the potential for GI perforation.
  • Patients with a known serious or severe hypersensitivity reaction to Movantik or any of its excipients.
  • Symptoms consistent with opioid withdrawal, including hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, and yawning, occurred in patients treated with Movantik.

Global Botulinum Toxin Market (2021 to 2030) - by Product Type, Application, Gender, Age Group, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 24, 2021
Health, Other Health, Patient, Diagnosis, Medical tourism, Skin, Woman, Man, Ageing, Urbanization, Hyperhidrosis, Face, Social media, China Biologic Products, Growth, Population, International Society, Pharmaceutical industry, Canning, Health insurance

This upsurge in aesthetic consciousness among the population, coupled with the increase in the availability of minimally invasive procedures, is further supplementing the market growth.

Key Points: 
  • This upsurge in aesthetic consciousness among the population, coupled with the increase in the availability of minimally invasive procedures, is further supplementing the market growth.
  • Moreover, the rising number of people opting for cosmetic procedures is directly boosting the botulinum toxin market growth.
  • These repetitions limit the growth of the botulinum toxin market since patients are reluctant to opt for repetitive procedures.
  • Moreover, the higher cost of these procedures and subsequent adverse effects further impedes market growth over the forecast period.

Brickell Biotech Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 9, 2021
NDA, Graduate, Exocrine gland, Insurance, Growth, COVID-19, Policy, Acquisition, Therapy, Nervous system, Research, Degenerative disease, Anticholinergic, Safety, DYRK1A, Leadership, Blood, Trial of the century, Rheumatoid arthritis, Benaroya Research Institute, Humanitarian use licenses, Conference, GLOBE, Inflammation, T helper cell, Time, Patient, Atopic dermatitis, FDA, Private Securities Litigation Reform Act, Virginia Mason Medical Center, U.S. Securities and Exchange Commission, NCE, SEC, Pharmacokinetics, University of Florida, Autoimmunity, University, Immune system, Hyperhidrosis, Company, Acetylcholine, Nasdaq, BBI, Intellectual property, Pharmaceutical industry, Vaccine, Cryptocurrency, Lithium

BOULDER, Colo., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune, and other debilitating diseases, today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Key Points: 
  • Research and development expenses were $10.2million for the third quarter of 2021, compared to $1.3million for the third quarter of 2020.
  • Brickells net loss was $13.3million for the third quarter of 2021 compared to $4.3million for the third quarter of 2020.
  • A live webcast of the conference call can be accessed at http://public.viavid.com/index.php?id=146695 or through the Brickell Biotech website at https://ir.brickellbio.com.
  • In August 2021, Brickell acquired exclusive, worldwide rights to research, develop, and commercialize novel therapeutics generated from a proprietary DYRK1A inhibitor platform.

Brickell Biotech to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on November 9, 2021

Retrieved on: 
Monday, November 1, 2021
Leadership, Humanitarian use licenses, Hyperhidrosis, BBI, Nasdaq, Patient, Therapy, Autoimmunity, GLOBE, Investor, Webcast, Brickell, Pharmaceutical industry

Brickells management will host a conference call and webcast at 4:30 pm ET on Tuesday, November 9th to discuss the financial results and recent corporate highlights.

Key Points: 
  • Brickells management will host a conference call and webcast at 4:30 pm ET on Tuesday, November 9th to discuss the financial results and recent corporate highlights.
  • To access the call, please dial 877-705-6003 in the U.S. or 201-493-6725 outside the U.S. and provide the conference ID number: 13723603.
  • To access the live webcast, please go to the Investors section of Brickells website at https://ir.brickellbio.com/events-presentations .
  • Brickell Biotech, Inc. is a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases.

Brickell Biotech Prices Public Offering of Common Stock

Retrieved on: 
Thursday, October 28, 2021
Research, Oppenheimer, William Blair & Company, SEC filing, Hyperhidrosis, Security (finance), U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, Policy, SEC, Leadership, Humanitarian use licenses, Time, Company, COVID-19, Attention, Nasdaq, BBI, Prospectus, Therapy, Autoimmunity, Intellectual property, GLOBE, Sale, Form, Pharmaceutical industry

In addition, Brickell has granted the underwriters a 30-day option to purchase up to 3,947,400 additional shares of common stock at the public offering price, less the underwriting discount.

Key Points: 
  • In addition, Brickell has granted the underwriters a 30-day option to purchase up to 3,947,400 additional shares of common stock at the public offering price, less the underwriting discount.
  • The gross proceeds from the public offering, before deducting the underwriting discount and offering expenses payable by Brickell, are expected to be approximately $10.0 million.
  • Brickell intends to use the net proceeds of this offering for research and development, including clinical trials, working capital, business development and general corporate purposes.
  • The forward-looking statements represent the estimates of Brickell as of the date hereof only, and Brickell specifically disclaims any duty or obligation to update forward-looking statements.